An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic Adenocarcinoma
Clinical trial NCT06015321 · UNKNOWN
Trial details
- NCT number
- NCT06015321
- Sponsor
- Samsung Medical Center
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-01
- Primary completion
- 2025-10-31
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.